Due to RM191A's activities we have developed a strong and diverse R&D pipeline across a range of indications.

The treatment of neuropathic pain is our most advanced indication, having completed a phase 2a pilot study. We are in preparation to begin our phase 2/3 study in severe peripheral neuropathic pain.

The treatment of UV skin damage (sunburn) is our second most advanced application of RM191A.